Education
About Us
Working with TipRanks
Follow Us
Towa Pharmaceutical Co Ltd (TWAPF)
OTHER OTC:TWAPF
Total Valuation
Towa Pharmaceutical Co has a market cap or net worth of $1.21B. The enterprise value is $369.81B.
Market Cap$1.21B
Enterprise Value$369.81B
Share Statistics
Towa Pharmaceutical Co has 51,516,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,516,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Towa Pharmaceutical Co’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 3.21%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)3.21%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee49.68M
Profits Per Employee3.53M
Employee Count4,588
Asset Turnover0.53
Inventory Turnover1.45
Valuation Ratios
The current PE Ratio of Towa Pharmaceutical Co is 9.1. Towa Pharmaceutical Co’s PEG ratio is 0.40.
PE Ratio9.1
PS Ratio0.51
PB Ratio0.77
Price to Fair Value0.89
Price to FCF-24.72
Price to Operating Cash Flow―
PEG Ratio0.40
Income Statement
In the last 12 months, Towa Pharmaceutical Co had revenue of 227.93B and earned 16.17B in profits. Earnings per share was 328.58.
Revenue227.93B
Gross Profit81.38B
Operating Income17.65B
Pretax Income24.46B
Net Income16.17B
EBITDA35.54B
Earnings Per Share (EPS)328.58
Cash Flow
In the last 12 months, operating cash flow was 5.70B and capital expenditures -21.91B, giving a free cash flow of -16.21B billion.
Operating Cash Flow5.70B
Free Cash Flow-16.21B
Free Cash Flow per Share-314.74
Dividends & Yields
Towa Pharmaceutical Co pays an annual dividend of $0.254, resulting in a dividend yield of 3.18%
Dividend Per Share$0.254
Dividend Yield3.18%
Payout Ratio19.88%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change31.04%
50-Day Moving Average25.33
200-Day Moving Average24.14
Relative Strength Index (RSI)99.88
Average Volume (3m)0.00
Important Dates
Towa Pharmaceutical Co upcoming earnings date is May 14, 2026, TBA (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateMay 14, 2026
Ex-Dividend Date―
Financial Position
Towa Pharmaceutical Co as a current ratio of 2.72, with Debt / Equity ratio of ―
Current Ratio2.72
Quick Ratio1.46
Debt to Market Cap1.45
Net Debt to EBITDA4.86
Interest Coverage Ratio18.63
Taxes
In the past 12 months, Towa Pharmaceutical Co has paid 8.29B in taxes.
Income Tax8.29B
Effective Tax Rate0.34
Enterprise Valuation
Towa Pharmaceutical Co EV to EBITDA ratio is 8.78, with an EV/FCF ratio of -10.03.
EV to Sales1.37
EV to EBITDA8.78
EV to Free Cash Flow-10.03
EV to Operating Cash Flow37.99
Balance Sheet
Towa Pharmaceutical Co has $29.25B in cash and marketable securities with $236.26B in debt, giving a net cash position of -$194.23B billion.
Cash & Marketable Securities$29.25B
Total Debt$236.26B
Net Cash-$194.23B
Net Cash Per Share-$3.77K
Tangible Book Value Per Share$2.14K
Margins
Gross margin is ―, with operating margin of 7.74%, and net profit margin of 7.10%.
Gross Margin―
Operating Margin7.74%
Pretax Margin10.73%
Net Profit Margin7.10%
EBITDA Margin15.59%
EBIT Margin7.74%
Analyst Forecast
The average price target for Towa Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―